<DOC>
	<DOCNO>NCT00360295</DOCNO>
	<brief_summary>To evaluate clinical efficacy safety patient mild moderate community-acquired pneumonia receive dose 2 g azithromycin SR formulation .</brief_summary>
	<brief_title>A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<criteria>Patients diagnose mild moderate severity classification pneumonia `` Clinical evaluation method new antimicrobial agent treat respiratory infection : Report Committee Respiratory System , Japan Society Chemotherapy ( establish 2000 ) '' . Severe underlying disease ; patient drug clinical evaluation difficult confounding disease . ( `` Severe '' assess Severity underlie disease complication `` Clinical evaluation method new antimicrobial agent treat respiratory infection ( draft ) '' Japan Society Chemotherapy ( 1997 ) ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>